Gryphon Bio Inc.
San Antonio, TX
- UEI
- GNX8BTRL8915
- CAGE
- 84CH5
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 200 E Grayson St #101, San Antonio, TX 78215, USA
- Website
- gryphonbio.com
- Founded
- 2018
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| New research and development contract award for the feasibility study of a single platform solution for blood testing… | Defense Health Agency | $749,437 |
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Aivocode, Inc. | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Neurovation Labs Inc. | New York, NY | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Neurodex Inc. | Natick, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| The Sheba Fund For Health Services And Research (R.a.) | Rehovot, Center District | 622110 General Medical and Surgical Hospitals |
| CND Life Sciences, Inc. | Scottsdale, AZ | 621511 Medical Laboratories |
About the company
Gryphon Bio Inc. is an early stage company specializing in diagnostic powered therapeutics for brain health. Through federal contracts and grants, the company provides research and development services related to biomarkers and treatments for traumatic brain injury (TBI) and associated conditions like Alzheimer's disease.
Gryphon Bio has received one prime federal contract, a $749,437 definitive fixed price level of effort contract from the Defense Health Agency to conduct a feasibility study on a single platform blood test for TBI biomarkers. The 2-year contract runs from September 2022 through December 2024.
Through federal grants, Gryphon Bio has received awards to develop home-based tests for assessing risk of Alzheimer's disease in TBI veterans ($2.5 million from the Defense Health Agency); perform proof-of-concept studies on novel SGP130-FC bioconjugates for rehabilitation treatment of TBI ($484,997 from the National Institutes of Health); develop monoclonal antibody immunotherapies targeting GFAP protein debris from astrocytes injured during TBI ($1.5 million from the National Institutes of Health); create rapid plasma and saliva tests detecting TBI sequelae ($2.8 million from the Department of the Army); and develop anti-Tau DNA aptamers as tools for TBI and Alzheimer's research ($588,804 from the Defense Health Agency).
Quick answers
Is Gryphon Bio Inc. registered in SAM.gov?
Yes. Gryphon Bio Inc.'s SAM.gov registration is active through May 21, 2027.
What is Gryphon Bio Inc.'s most recent federal award?
Gryphon Bio Inc.'s most recent federal grant award is Highly scalable and cost-effective home-based sampling and testing solution for glymphatic clearance/impairment in… (HT94252310392), from Defense Health Agency, on May 15, 2023.
On GovTribe
See Gryphon Bio Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors